ATE495738T1 - Neue medizinische verwendung von alpha- ketoglutarat - Google Patents

Neue medizinische verwendung von alpha- ketoglutarat

Info

Publication number: ATE495738T1
Authority: AT; Austria
Prior art keywords: bacteria; ureolytic; ureolytic bacteria; ketoglutarate; infections
Prior art date: 2006-07-03

Application number

AT07460015T

Other languages

English (en)

Inventor

Danuta Kruszewska

Original Assignee

Danuta Kruszewska

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-07-03

Filing date

2007-07-03

Publication date

2011-02-15

2007-07-03 Application filed by Danuta Kruszewska filed Critical Danuta Kruszewska

2011-02-15 Application granted granted Critical

2011-02-15 Publication of ATE495738T1 publication Critical patent/ATE495738T1/de

Links

KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 title abstract 3
241000894006 Bacteria Species 0.000 abstract 8
230000003604 ureolytic effect Effects 0.000 abstract 6
208000015181 infectious disease Diseases 0.000 abstract 4
230000015572 biosynthetic process Effects 0.000 abstract 3
241000251468 Actinopterygii Species 0.000 abstract 2
241000590002 Helicobacter pylori Species 0.000 abstract 2
241000282414 Homo sapiens Species 0.000 abstract 2
241000124008 Mammalia Species 0.000 abstract 2
241000202898 Ureaplasma Species 0.000 abstract 2
108010046334 Urease Proteins 0.000 abstract 2
241000251539 Vertebrata <Metazoa> Species 0.000 abstract 2
230000000694 effects Effects 0.000 abstract 2
229940037467 helicobacter pylori Drugs 0.000 abstract 2
238000002360 preparation method Methods 0.000 abstract 2
238000011321 prophylaxis Methods 0.000 abstract 2
241000271566 Aves Species 0.000 abstract 1
241000589562 Brucella Species 0.000 abstract 1
241000186216 Corynebacterium Species 0.000 abstract 1
208000006558 Dental Calculus Diseases 0.000 abstract 1
241000282412 Homo Species 0.000 abstract 1
241000588748 Klebsiella Species 0.000 abstract 1
241001465754 Metazoa Species 0.000 abstract 1
241001430197 Mollicutes Species 0.000 abstract 1
241000204048 Mycoplasma hominis Species 0.000 abstract 1
241000588769 Proteus <enterobacteria> Species 0.000 abstract 1
241000588770 Proteus mirabilis Species 0.000 abstract 1
241000588768 Providencia Species 0.000 abstract 1
241000589516 Pseudomonas Species 0.000 abstract 1
241000193395 Sporosarcina pasteurii Species 0.000 abstract 1
241000191940 Staphylococcus Species 0.000 abstract 1
241000607734 Yersinia <bacteria> Species 0.000 abstract 1
239000003674 animal food additive Substances 0.000 abstract 1
230000001580 bacterial effect Effects 0.000 abstract 1
208000002925 dental caries Diseases 0.000 abstract 1
235000015872 dietary supplement Nutrition 0.000 abstract 1
239000002778 food additive Substances 0.000 abstract 1
210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
208000024693 gingival disease Diseases 0.000 abstract 1
230000002458 infectious effect Effects 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
210000000214 mouth Anatomy 0.000 abstract 1
210000004400 mucous membrane Anatomy 0.000 abstract 1
210000005000 reproductive tract Anatomy 0.000 abstract 1
230000000241 respiratory effect Effects 0.000 abstract 1
210000002345 respiratory system Anatomy 0.000 abstract 1
238000011282 treatment Methods 0.000 abstract 1
230000002485 urinary effect Effects 0.000 abstract 1
210000002229 urogenital system Anatomy 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nutrition Science (AREA)
Polymers & Plastics (AREA)
Food Science & Technology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Mycology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Fodder In General (AREA)
Detergent Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT07460015T 2006-07-03 2007-07-03 Neue medizinische verwendung von alpha- ketoglutarat ATE495738T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PL380103A PL226695B1 (pl)	2006-07-03	2006-07-03	Środek do zastosowania w zapobieganiu i/lub hamowaniu kolonizacji Helicobacter pylori, zastosowanie soli kwasu alfa‑ketoglutarowego z metalami alkalicznymi i ziem alkalicznych do wytwarzania środka leczniczego oraz dodatku do żywności do zapobiegania i/lub hamowania kolonizacji Helicobacter pylori

Publications (1)

Publication Number	Publication Date
ATE495738T1 true ATE495738T1 (de)	2011-02-15

Family

ID=38984524

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT07460015T ATE495738T1 (de)	2006-07-03	2007-07-03	Neue medizinische verwendung von alpha- ketoglutarat

Country Status (10)

Country	Link
US (1)	US20100124537A1 (de)
EP (1)	EP1917959B1 (de)
AT (1)	ATE495738T1 (de)
DE (1)	DE602007012036D1 (de)
DK (1)	DK1917959T3 (de)
ES (1)	ES2360142T3 (de)
HR (1)	HRP20110268T1 (de)
IL (1)	IL233342A (de)
PL (2)	PL226695B1 (de)
SI (1)	SI1917959T1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7981908B2 (en)	2005-05-11	2011-07-19	Vecta, Ltd.	Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en)	2005-05-11	2010-09-28	Vecta, Ltd.	Composition and methods for inhibiting gastric acid secretion
PL2046334T3 (pl)	2006-07-25	2015-02-27	Vecta Ltd	Kompozycje i sposoby hamowania wydzielania kwasów żołądkowych z wykorzystaniem pochodnych małych kwasów dikarboksylowych w połączeniu z PPI
SE0602446L (sv) *	2006-11-16	2008-05-17	Entress Ab	Ny användning av kända farmakologiskt aktiva kemiska sammansättningar
EP2468319B1 (de)	2010-11-29	2016-11-23	Eurochit Danuta Kruszewska	Neues Nanoprodukt zur Verwendung bei der Prophylaxe, Diagnose sowie bei der medizinischen and veterinärmedizinischen Behandlung
CN104684565A (zh)	2012-05-29	2015-06-03	达努塔·克鲁谢夫斯卡	在人类和兽医的预防和医疗中有用的、包含罗伊氏乳杆菌dan080的纳米产品及其医疗用途
EP2674162A1 (de)	2012-05-29	2013-12-18	Danuta Kruszewska	Nanoprodukt, beinhaltend lactobacillus reuteri dan080, zur verwendung bei der prophylaxe, diagnose sowie bei der medizinischen and veterinärmedizinischen behandlung
CA2884592C (en)	2012-09-19	2021-08-31	Grespo Ab	Compositions for improvement of brain function
CN103923900B (zh) *	2014-04-14	2016-03-23	江南大学	一种黄酒用双功能酶交联酶聚集体的制备与应用
EP3518915A4 (de) *	2016-09-30	2020-04-15	The Regents of the University of California	Alpha-ketobutyrat, alpha-ketoglutarat und 2-hydroxybutyrat zur stimulierung des haarwachstums
SG10202107237SA (en) *	2017-04-25	2021-08-30	Buck Inst Res Aging	Formulations for extending lifespan and healthspan
KR102833111B1 (ko)	2018-09-25	2025-07-10	폰세 드 리온 헬스 데지그네이티드 액티비티 컴퍼니	칼슘 알파-케토글루타레이트의 제조 방법
WO2020086733A1 (en) *	2018-10-24	2020-04-30	Ponce De Leon Health Designated Activity Company	Nicotinamide riboside compositions for healthspan extension
CA3188646A1 (en) *	2020-07-02	2022-01-06	Ponce De Leon Health Designated Activity Company	Compositions and methods for treating crp-mediated diseases
CN115340313B (zh) *	2022-01-17	2023-04-18	浙江理工大学	一种物理复合微生物技术强化再生骨料方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS4919855B1 (de)	1970-10-06	1974-05-21
US4256731A (en) *	1978-03-23	1981-03-17	Beecham, Inc.	Oral Compositions
US5028412A (en) *	1987-05-01	1991-07-02	Purdue Research Foundation	Oral compositions comprising anti-calculus agents
US5817294A (en) *	1990-11-02	1998-10-06	Arnold; Michael J.	Plaque adsorbent oral composition and method
JP2002529545A (ja) *	1998-11-06	2002-09-10	ユニベルシテドゥモントリオール	バイオフィルムを除去するための改良型の殺菌性及び非殺菌性溶液
FR2822704B1 (fr) *	2001-03-29	2005-02-18	Chiesi Sa	Sels de cetoacides et d'acides amines gastroresistants et leur utilisation pour la preparation de medicaments
US7122578B2 (en) *	2001-09-11	2006-10-17	Alain Martin	Method and composition for treating mammalian diseases and injuries which cause pain, erythema, swelling, crusting, ischemia scarring and excess white blood cell infiltration
SE0200256D0 (sv) *	2001-12-21	2002-01-29	Gramineer Internat Ab	New composition, methods and use
PL368572A1 (en) *	2004-06-17	2005-12-27	Sgp & Sons Ab	Pharmaceutical compound for prevention and therapy of increased level of cholesterol, ldl and triglycerides as well as application of the pharmaceutical compound as an agent acting against atherosclerosis and used in circulatory system affections
US7803817B2 (en) *	2005-05-11	2010-09-28	Vecta, Ltd.	Composition and methods for inhibiting gastric acid secretion
AU2006316059A1 (en)	2005-11-15	2007-05-24	Entress Ab	Medicament for use in connection with cartilage impairment
KR20080102372A (ko) *	2006-01-19	2008-11-25	엔트레스 에이비	진단 방법 및 치료 방법

2006
- 2006-07-03 PL PL380103A patent/PL226695B1/pl unknown
2007
- 2007-07-03 US US12/452,485 patent/US20100124537A1/en not_active Abandoned
- 2007-07-03 ES ES07460015T patent/ES2360142T3/es active Active
- 2007-07-03 DK DK07460015.6T patent/DK1917959T3/da active
- 2007-07-03 SI SI200730571T patent/SI1917959T1/sl unknown
- 2007-07-03 AT AT07460015T patent/ATE495738T1/de active
- 2007-07-03 EP EP07460015A patent/EP1917959B1/de active Active
- 2007-07-03 DE DE602007012036T patent/DE602007012036D1/de active Active
- 2007-07-03 PL PL07460015T patent/PL1917959T3/pl unknown
2011
- 2011-04-13 HR HR20110268T patent/HRP20110268T1/hr unknown
2014
- 2014-06-24 IL IL233342A patent/IL233342A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
SI1917959T1 (sl)	2011-05-31
PL226695B1 (pl)	2017-08-31
IL233342A0 (en)	2014-08-31
EP1917959B1 (de)	2011-01-19
PL1917959T3 (pl)	2011-06-30
IL233342A (en)	2016-05-31
DE602007012036D1 (de)	2011-03-03
DK1917959T3 (da)	2011-05-09
US20100124537A1 (en)	2010-05-20
EP1917959A1 (de)	2008-05-07
PL380103A1 (pl)	2008-01-07
ES2360142T3 (es)	2011-06-01
HRP20110268T1 (hr)	2011-05-31

Legal Events

Date

Code

Title

Description

2011-11-15

UEP

Publication of translation of european patent specification

Ref document number: 1917959

Country of ref document: EP

Publication	Publication Date	Title
ATE495738T1 (de)	2011-02-15	Neue medizinische verwendung von alpha- ketoglutarat
BRPI0902901B8 (pt)	2021-05-25	bacteriófago e composição antibacteriana, alimento para animais, água potável, desinfetante, agente de limpeza e método para tratamento de doenças infecciosas compreendendo o mesmo
JP2019524877A5 (de)	2020-07-27
BR112021022632A2 (pt)	2022-01-04	Composições e métodos para tratar condições pulmonares relacionadas a biofilmes
EP3986394A1 (de)	2022-04-27	Biofilmunterbrechung
Licker et al.	2017	Microbial biofilm in human health-an updated theoretical and practical insight
CN103690937A (zh)	2014-04-02	一种含海洋生物成分的儿童用龋齿口腔喷剂及其制备方法
CN104041516A (zh)	2014-09-17	一种禽畜养殖屋消毒剂
HRP20110479T1 (hr)	2011-07-31	Prirodna mineralna voda za upotrebu kod profilakse, higijene i tretmana zuba i paradontnih bolesti
NO993774D0 (no)	1999-08-04	Carbapenem-forbindelse, anvendelse herav og intermediær forbindelse herav
Ponnuraj et al.	2015	Influence of Limonia acidissima L. against the biofilm forming Aeromonas hydrophila isolated from fresh water fishes
Ismail et al.	2019	Silver nanoparticles and sodium hypochlorite inhibitory effects on biofilm produced by Pseudomonas aeruginosa from poultry farms
JP2010095489A (ja)	2010-04-30	病原性細菌の毒素産生抑制剤
Kishimoto et al.	2007	Mechanical tooth cleaning before chlorhexidine application
Magdalenić et al.	2010	Antibacterial activity of Croatian honey of different botanical origin
Moses-Otutu et al.	2021	Microbial contamination of tooth brushes and tooth brush keeping places among apparently healthy individuals in Egor LGA, Benin City
RU2583890C2 (ru)	2016-05-10	Способ лечения гингивитов, пародонтитов и зубного камня у собак
W Williams et al.	2012	The oral cavity, biofilms and ventilator-associated pneumonia
Panigrahi et al.	2024	TOPIC: IMMUNOGLOBULIN Y IN IMPROVING ORAL HEALTH IN CHILDREN: A COMPREHENSIVE REVIEW
EA201892278A1 (ru)	2019-04-30	Анбитактериальные биароматические производные с оксетан-3-илокси замещением
Polanco Z et al.	2006	Gastric lesions associated with the presence of bacteria of the helicobacter genusin canine
WO2018039244A1 (en)	2018-03-01	5-benzylidene-4-oxazolidinones
Panigrahi et al.	2024	Immunoglobulin Y In Improving Oral Health In Children: A Comprehensive Review
BRPI0605658B8 (pt)	2021-05-25	peptídeo antibiótico rico em glicina derivado de planta
Aliabadi et al.	2024	Effects of Mouthwash Matrica and Chlorhexidine in Preventing Nosocomial Pneumonia in the Intensive Care Unit: A Systematic Review